Study of Relvar Ellipta (fluticasone furoate /vilanterol) in chronic obstructive pulmonary disease published in New England Journal of Medicine- GlaxoSmithKline / Innoviva
GlaxoSmithKline and Innoviva announced that the results from the pioneering Salford Lung Study (SLS) have been published in the New England Journal of Medicine (NEJM). This study, which reported headline results in May 2016, was designed to evaluate the effectiveness and safety of Relvar Ellipta (fluticasone furoate �FF�/vilanterol �VI� or �FF/VI�) in patients with chronic obstructive pulmonary disease (COPD), compared with their �usual care� administered in an everyday clinical practice setting. For the primary endpoint in patients, who had exacerbated in the year before the study, treated with Relvar Ellipta there was a statistically significant reduction of 8.4% in the rate of moderate or severe exacerbations compared with patients receiving �usual care�.
The majority of these patients in the study on usual care were taking an inhaled corticosteroid containing regimen (88%). A similar reduction in exacerbations with FF/VI was seen in those patients on a treatment that included an ICS/ long-acting beta2-agonists at baseline. Data from the study are being presented at the European Respiratory Society International Congress.
See: "Effectiveness of Fluticasone Furoate�Vilanterol for COPD in Clinical Practice" J�rgen Vestbo et al. New England Journal of Medicine, September 4, 2016DOI: 10.1056/NEJMoa1608033.
Related news and insights
The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Cevenfacta, intended for the treatment of bleeding episodes.
Calliditas Therapeutics announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the granting of a conditional marketing authorisation for Kinpeygo for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (UPCR) greater than 1.5 g/gram.